Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.31 |
| ▸ | CTSD | P07339 | 1/20 | 0.30 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL432190 | 1.00 | MAPT (0.35) | MAPTALDH1A1PKMLMNATSHR | |
| SCHEMBL3053407 | 0.98 | ALDH1A1 (0.36) | MAPTALDH1A1PKMLMNATSHR | |
| SCHEMBL6652266 | 0.96 | KMT2A (0.35) | MAPTALDH1A1PKMLMNATSHR | |
| SCHEMBL17338063 | 0.93 | ALDH1A1 (0.36) | MAPTALDH1A1PKMLMNATSHR | |
| SCHEMBL9517429 | 0.93 | CRBN (0.35) | ALDH1A1PKMLMNATSHRCRBN | |
| SCHEMBL9733421 | 0.91 | MAPT (0.35) | MAPTALDH1A1PKMLMNATSHR | |
| SCHEMBL9733418 | 0.91 | MAPT (0.35) | MAPTALDH1A1PKMLMNATSHR | |
| SCHEMBL18150856 | 0.89 | SRD5A1 (0.37) | MAPTALDH1A1PKMLMNATSHR | |
| SCHEMBL3046579 | 0.89 | ALDH1A1 (0.36) | MAPTALDH1A1PKMLMNATSHR | |
| SCHEMBL6638258 | 0.89 | ALDH1A1 (0.36) | MAPTALDH1A1PKMLMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9498483-B2 | 2,3,5-trisubstituted thiophene compounds and uses thereof | NOVARTIS AG (CH) | 2016-11-22 | — | — | US | disclosed |
| US-9498483-B2 | 2,3,5-trisubstituted thiophene compounds and uses thereof | NOVARTIS AG (CH) | 2016-11-22 | — | — | US | disclosed |
| US-9498483-B2 | 2,3,5-trisubstituted thiophene compounds and uses thereof | NOVARTIS AG (CH) | 2016-11-22 | — | — | US | disclosed |
| US-20150224109-A1 | 2,3,5-Trisubstituted Thiophene Compounds and Uses Thereof | NOVARTIS AG (CH) | 2015-08-13 | — | — | US | disclosed |
| US-20150224109-A1 | 2,3,5-Trisubstituted Thiophene Compounds and Uses Thereof | NOVARTIS AG (CH) | 2015-08-13 | — | — | US | disclosed |
| US-20150224109-A1 | 2,3,5-Trisubstituted Thiophene Compounds and Uses Thereof | NOVARTIS AG (CH) | 2015-08-13 | — | — | US | disclosed |
| US-9040690-B2 | 2,3,5-trisubstituted thiophene compounds and uses thereof | NOVARTIS AG (CH) | 2015-05-26 | — | — | US | disclosed |
| US-9040690-B2 | 2,3,5-trisubstituted thiophene compounds and uses thereof | NOVARTIS AG (CH) | 2015-05-26 | — | — | US | disclosed |
| US-9040690-B2 | 2,3,5-trisubstituted thiophene compounds and uses thereof | NOVARTIS AG (CH) | 2015-05-26 | — | — | US | disclosed |
| EP-2595983-A1 | 2,3,5-TRISUBSTITUTED THIOPHENE COMPOUNDS AND USES THEREOF | Novartis AG (CH) | 2013-05-29 | — | — | EP | disclosed |
| US-20130123252-A1 | 2,3,5-Trisubstituted Thiophene Compounds and Uses Thereof | NOVARTIS AG (CH) | 2013-05-16 | — | — | US | disclosed |
| US-20130123252-A1 | 2,3,5-Trisubstituted Thiophene Compounds and Uses Thereof | NOVARTIS AG (CH) | 2013-05-16 | — | — | US | disclosed |
| US-20130123252-A1 | 2,3,5-Trisubstituted Thiophene Compounds and Uses Thereof | NOVARTIS AG (CH) | 2013-05-16 | — | — | US | disclosed |
| WO-2012010663-A9 | 2,3,5-TRISUBSTITUTED THIOPHENE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2013-01-24 | — | — | WO | disclosed |
| WO-2012010663-A1 | 2,3,5-TRISUBSTITUTED THIOPHENE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150224109-A1 | 2,3,5-Trisubstituted Thiophene Compounds and Uses Thereof | TPMT, CYP3A5, CYP11B2 | MAPT 2512/4885ALDH1A1 283/4885PKM 1690/4885 |
| US-20130123252-A1 | 2,3,5-Trisubstituted Thiophene Compounds and Uses Thereof | TPMT, CYP3A5, CYP11B2 | MAPT 2512/4885ALDH1A1 283/4885PKM 1690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.